564 related articles for article (PubMed ID: 26222874)
1. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
[TBL] [Abstract][Full Text] [Related]
2. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
3. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
[TBL] [Abstract][Full Text] [Related]
4. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.
Bouman C; van Herwaarden N; van den Hoogen F; van der Maas A; van den Bemt B; den Broeder AA
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):597-604. PubMed ID: 28425772
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
Nasser Y; Labetoulle R; Harzallah I; Berger AE; Roblin X; Paul S
Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
[TBL] [Abstract][Full Text] [Related]
6. Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of Adalimumab.
Bian S; Ferrante M; Gils A
AAPS J; 2017 Mar; 19(2):468-474. PubMed ID: 27873119
[TBL] [Abstract][Full Text] [Related]
7. Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA.
Ogrič M; Žigon P; Lakota K; Praprotnik S; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S
Clin Rheumatol; 2019 Feb; 38(2):361-370. PubMed ID: 30014359
[TBL] [Abstract][Full Text] [Related]
8. Anti-infliximab antibodies: How to compare old and new data?
Imbrechts M; Van Stappen T; Compernolle G; Tops S; Gils A
J Pharm Biomed Anal; 2020 Jan; 177():112842. PubMed ID: 31526960
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.
Van Stappen T; Vande Casteele N; Van Assche G; Ferrante M; Vermeire S; Gils A
Gut; 2018 May; 67(5):818-826. PubMed ID: 28450388
[TBL] [Abstract][Full Text] [Related]
11. Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay.
Hock BD; McKenzie JL; Goddard L; Smith SM; McEntyre CJ; Keating PE
Ther Drug Monit; 2018 Dec; 40(6):705-715. PubMed ID: 30439789
[TBL] [Abstract][Full Text] [Related]
12. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
Chen DY; Chen YM; Hsieh TY; Hung WT; Hsieh CW; Chen HH; Tang KT; Lan JL
Rheumatology (Oxford); 2016 Jan; 55(1):143-8. PubMed ID: 26324949
[TBL] [Abstract][Full Text] [Related]
13. Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay.
Weisshof R; Ungar B; Blatt A; Dahan A; Pressman S; Waterman M; Kopylov U; Ben-Horin S; Chowers Y
Inflamm Bowel Dis; 2016 Jul; 22(7):1655-61. PubMed ID: 27120567
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
Freeman K; Connock M; Auguste P; Taylor-Phillips S; Mistry H; Shyangdan D; Court R; Arasaradnam R; Sutcliffe P; Clarke A
Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
[TBL] [Abstract][Full Text] [Related]
15. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.
Gorovits B; Baltrukonis DJ; Bhattacharya I; Birchler MA; Finco D; Sikkema D; Vincent MS; Lula S; Marshall L; Hickling TP
Clin Exp Immunol; 2018 Jun; 192(3):348-365. PubMed ID: 29431871
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.
Quistrebert J; Hässler S; Bachelet D; Mbogning C; Musters A; Tak PP; Wijbrandts CA; Herenius M; Bergstra SA; Akdemir G; Johannesson M; Combe B; Fautrel B; Chollet-Martin S; Gleizes A; Donnellan N; Deisenhammer F; Davidson J; Hincelin-Mery A; Dönnes P; Fogdell-Hahn A; De Vries N; Huizinga T; Abugessaisa I; Saevarsdottir S; Hacein-Bey-Abina S; Pallardy M; Broët P; Mariette X;
Semin Arthritis Rheum; 2019 Jun; 48(6):967-975. PubMed ID: 30420245
[TBL] [Abstract][Full Text] [Related]
17. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
Valor L; Hernández-Flórez D; de la Torre I; Llinares F; Rosas J; Yagüe J; Garrido J; Naredo E
Clin Exp Rheumatol; 2015; 33(5):617-23. PubMed ID: 26316061
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
Expert Opin Drug Saf; 2016 Jan; 15(1):43-52. PubMed ID: 26559805
[TBL] [Abstract][Full Text] [Related]
19. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations.
van Bezooijen JS; Koch BC; van Doorn MB; Prens EP; van Gelder T; Schreurs MW
Ther Drug Monit; 2016 Aug; 38(4):432-8. PubMed ID: 27120178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]